An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
PureTech to Present at the UBS Global Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
PureTech Health plc (LSE:PRTC, Nasdaq:PRTC) has announced that CFO George Farmer, Ph.D., will present at the UBS Global Healthcare Conference on May 24, 2022, at 10:45am EDT. The presentation will be available via webcast on the company's investor relations website. PureTech is focused on developing biotherapeutics for serious diseases and has a pipeline of 27 therapeutics, including two with FDA clearance and European marketing authorization. The company emphasizes innovation in immunology and drug development.
Positive
None.
Negative
None.
BOSTON--(BUSINESS WIRE)--
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that George Farmer, Ph.D., Chief Financial Officer, will present at the UBS Global Healthcare Conference on Tuesday, May 24, 2022, at 10:45am EDT. A webcast of the presentation will be available at https://investors.puretechhealth.com.
PureTech’s George Farmer, Chief Financial Officer, will present at the UBS Global Healthcare Conference on Tuesday, May 24, 2022, at 10:45am EST. (Photo: Business Wire)
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders.
This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech's most recently filed Annual Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on unique insights in immunology and drug development.
For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to our upcoming presentation at the UBS Global Healthcare Conference and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2021 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
When will PureTech Health present at the UBS Global Healthcare Conference?
PureTech Health will present at the UBS Global Healthcare Conference on May 24, 2022, at 10:45am EDT.
Who is the CFO of PureTech Health?
The CFO of PureTech Health is George Farmer, Ph.D.
Where can I watch the PureTech Health presentation?
The presentation can be viewed via webcast on PureTech Health's investor relations website.
What is PureTech Health's focus in biotherapeutics?
PureTech Health focuses on discovering and developing medicines for severe diseases, including inflammatory, fibrotic, immunological, and neurological conditions.
How many therapeutics are in PureTech Health's pipeline?
PureTech Health has a pipeline consisting of 27 therapeutics and therapeutic candidates.
